Location: United States
Employees: 11-50
Total raised: $66.5M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 06.02.2022 | Takeda Ven... | takeda.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.10.2025 | - | $28M | Proxima Ve... |
| 28.07.2022 | Series B | $38.5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 16.10.2025 | BridGene Biosciences Raises $28M in Series B+ Funding | BridGene Biosciences, Inc., a San Jose, CA-based leader in the discovery and development of small molecule drugs for traditionally “hard-to-drug” targets, closed a $28m Series B+ financing round. The round was led by Bayland Capital, with p... |
| 28.07.2022 | Instacart’s comedown speaks volumes about the plight of digital retail | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The summer of 2022 is proving to be a long and lonely one for digital retail. Paid Content Migrat... |
| 28.07.2022 | BridGene Biosciences Raises $38.5M in Series B Financing | BridGene Biosciences, Inc., a San Jose, CA-based biotechnology company leveraging a proprietary chemoproteomic platform to discover and develop small-molecule drugs for high-value, traditionally undruggable targets, closed a $38.5m Series B... |
| - | BridGene Biosciences | “Bridging Undruggable Targets and Precision Medicines. Small molecule drug discovery and development for hard-to-drug targets.” |